Please login to the form below

Not currently logged in

Mundipharma appoints Paul Medeiros head of corporate and business development

He joins from AVI BioPharma and will lead Mundipharma's corporate growth across Europe

Paul Medeiros - MundipharmaAVI BioPharma's Paul Medeiros has joined Mundipharma as head of corporate and business development.

Medeiros will also join the executive leadership team at the UK-based group, which controls Napp in the UK and has associated companies in 32 other European countries.

His role will be to extend and expand areas for growth within this European network of companies.

“Paul's deep experience and network in the pharma industry, combined with his entrepreneurial mind-set and nuanced understanding of the business, will be essential for Mundipharma's continued growth,” said Antony Mattessich, regional director at Mundipharma Europe.

Medeiros was most recently senior VP and chief business officer at AVI BioPharma, a company focused on the development of RNA-based therapeutics for rare diseases.

Other roles in his 19-year career in the biopharma industry include VP, global licensing and strategic alliances for Schering-Plough, as well as several positions in sales and marketing at Merck & Co.

He has been involved with licensing and strategic partnering initiatives in specialist therapy areas, as well as technology acquisitions.

9th March 2012


Featured jobs

Subscribe to our email news alerts


Add my company
VCCP Health

We’re the challenger agency for challenger brands. Brands with a point to prove. Rx, OTC and wellness brands run by...

Latest intelligence

How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...
figure 1
The valuable brand
Creating value beyond the pill is both possible and increasingly necessary...